New COVID-19 Variant 'Cicada' Identified and Spreading

On November 22, 2024, a respiratory sample collected from a five-year-old child in South Africa yielded something unusual: a descendant of Omicron subvariant BA.3, a lineage that had not been detected in circulation since early 2022 [1]. For more than two years, the virus had evolved somewhere beyond the reach of genomic surveillance. When it resurfaced — carrying more than 70 mutations in its spike protein — researchers gave it a name that stuck: Cicada.

Now, sixteen months after that initial detection, BA.3.2 has been confirmed in at least 23 countries and 29 U.S. states [1][2]. It accounts for roughly 30% of sequenced COVID cases in Denmark, Germany, and the Netherlands [3], and an estimated 11% of U.S. cases as of March 2026 [4]. The question facing public health officials, clinicians, and a fatigued public is whether Cicada represents a genuine threat — or the latest iteration of a familiar cycle in which a new variant generates headlines disproportionate to its clinical impact.

The Mutations: Catalogued vs. Characterized

BA.3.2's defining feature is its genetic distance from currently circulating variants. Relative to LP.8.1, the strain targeted by the 2025–2026 COVID vaccine, Cicada carries 70 to 75 spike protein substitutions and deletions [1][5]. That total includes 20 changes in the receptor-binding domain (RBD) — the region most critical for cell entry and antibody recognition — and 35 in the N-terminal domain [1]. The variant also features deletions at spike sites 136–147 and 243–244, plus a four-amino-acid insertion after site 214 [1].

For context, the JN.1 and LP.8.1 lineages that dominated through 2025 carried roughly 30–40 spike mutations relative to the ancestral Wuhan strain [5]. Cicada nearly doubles that count.

Not all mutations are created equal. A study published in The Lancet Infectious Diseases found that BA.3.2 "exhibits potent antibody evasion, with mutations in important sites for neutralising antibody activity" [6]. But the CDC's own MMWR report noted a critical constraint: BA.3.2 sublineages showed "substantially reduced angiotensin-converting enzyme 2 (ACE2) binding and lung cell entry compared with XFG and NB.1.8.1" [1]. In other words, the same mutations that help Cicada dodge antibodies may also make it less efficient at infecting lung tissue — a trade-off that could limit both transmissibility and severity.

Two major sublineages have emerged: BA.3.2.1 and BA.3.2.2, the latter carrying four additional substitutions [1]. Researchers are tracking whether either sublineage develops enhanced fitness.

Spread: Fast in Europe, Slow in the U.S.

Cicada's trajectory has been uneven across geographies.

Source: CDC MMWR

Data as of Mar 12, 2026CSV

In the United States, BA.3.2 was first detected on June 27, 2025, at San Francisco International Airport, from a traveler returning from the Netherlands [1]. For months, it remained barely detectable. The CDC's genomic surveillance data from December 1, 2025, through February 11, 2026, found BA.3.2 in just 0.19% of 2,579 sequenced samples (95% CI: 0.06%–0.45%) [1]. By March 12, that figure had risen to 0.55% among 5,238 sequences [1]. By late March, estimates placed it at roughly 11% of U.S. cases [4].

Source: GISAID / CDC MMWR

Data as of Feb 11, 2026CSV

The European picture is different. Denmark, Germany, and the Netherlands each saw BA.3.2 reach approximately 30% of sequenced variants between November 2025 and January 2026 [1][3]. Yet a full strain replacement — where one variant drives out all others — has not occurred. The CDC's MMWR report observed that BA.3.2 has "cocirculated with various JN.1 descendant lineages with prevalences of approximately 10%–40%" rather than rapidly dominating [1].

This pattern differs from the early trajectories of Delta and Omicron, both of which achieved near-complete dominance within weeks of emergence in affected countries. Cicada's growth rate, while substantial, suggests it may settle into coexistence with other lineages rather than triggering a single massive wave.

Vaccine Effectiveness: Reduced but Not Eliminated

The 2025–2026 COVID vaccines target the LP.8.1 lineage. Against that strain and its close relatives, they perform well. Against Cicada, the picture is less encouraging.

Laboratory studies conducted by the CDC showed that BA.3.2 was the variant with the lowest antibody neutralization among seven variants tested against sera from LP.8.1-vaccinated individuals [1][6]. The Lancet Infectious Diseases study confirmed that updated vaccines still produce a neutralizing antibody response to BA.3.2, but that response is "noticeably weaker than against more closely matched strains like XFG" [6].

Dr. William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center, summarized the clinical implication: "Does the current vaccine provide some protection? Lab data would indicate yes, but not as much" [7][8].

Dr. Donald Milton of the University of Maryland offered a more reassuring framing: "Vaccines may not work well against infection, but will still probably protect against severe illness" [3]. This distinction matters. Neutralizing antibody titers — the standard lab measurement — correlate with protection against symptomatic infection but are a less precise predictor of protection against hospitalization and death, which also depends on T-cell responses and other immune mechanisms that are harder to measure in a lab [4][9].

The WHO has stated that current vaccines "are expected to continue providing protection against severe disease" from BA.3.2 [8]. No timeline for a Cicada-matched booster has been announced, but Dr. Robert H. Hopkins, medical director for the National Foundation for Infectious Diseases, noted that "the number of mutations from JN.1 viruses makes it less likely that the current vaccines will be highly effective against Cicada, but we need more data to better answer this question" [3]. For adults 65 and older, epidemiologist Katelyn Jetelina has recommended considering a spring dose if three months have passed since the last vaccination, with May–June timing aligning with likely seasonal patterns [4].

Severity: No Signal of Increased Harm — With Caveats

The most consequential question about any new variant is whether it makes people sicker. On Cicada, the early answer is cautiously reassuring.

Dr. Schaffner told PolitiFact that "early data indicates it is not more severe, or it doesn't have any distinctive clinical presentations" [3]. The CDC has reported no nationwide increase in severe disease attributable to BA.3.2, and case rates, emergency department visits, and hospitalizations have been trending downward [8][2].

The WHO's formal assessment classified BA.3.2 as posing "low additional public health risk compared with other circulating Omicron descendent lineages" [3][10].

Source: CDC / NCHS

Data as of Jun 1, 2024CSV

But the sample sizes behind these reassurances are small. As of March 12, 2026, only 29 clinical patient isolates of BA.3.2 had been identified in the U.S. [1]. Drawing robust conclusions about hospitalization and ICU rates from 29 cases — without stratification by age, comorbidity, or vaccination status — is not possible. The European data, drawn from countries where BA.3.2 has reached 30% prevalence, is more informative, and there too, no hospitalization surge has materialized [3][8]. Still, Dr. Celine Gounder, a CBS News medical contributor and KFF Health News editor, cautioned that absence of evidence is not evidence of absence at this stage [8].

The 2024–2025 respiratory season saw an estimated 390,000–550,000 COVID hospitalizations and 45,000–64,000 deaths nationwide [2]. From October 2025 through March 21, 2026, the CDC estimates 110,000–210,000 hospitalizations and 12,000–37,000 deaths [2]. These figures reflect the burden of all circulating variants, not Cicada specifically.

Who Is Most Vulnerable?

The populations most at risk from Cicada are the same ones that have borne the heaviest burden throughout the pandemic: the elderly, the immunocompromised, and individuals with chronic conditions.

COVID hospitalizations peaked at the end of December 2025 and early January 2026, with the highest rates among persons age 75 and older [7]. Unvaccinated high-risk individuals comprised the majority of hospitalized patients [7].

For immunocompromised patients — organ transplant recipients, cancer patients on chemotherapy, people with advanced HIV — Cicada's immune-evasive mutations are particularly concerning. These individuals often mount weaker antibody responses to vaccination, meaning the reduced neutralization seen in lab studies may translate more directly into reduced real-world protection [9].

On treatment, there is good news. Antiviral drugs including Paxlovid remain effective against BA.3.2 because they target viral replication machinery rather than the spike protein [9][10]. Monoclonal antibodies, which do target the spike, are more likely to see reduced efficacy, though no specific data on monoclonal performance against BA.3.2 was available at the time of reporting.

How Cicada Was Found — and What the Lag Reveals

The story of BA.3.2's detection is also a story about the state of global genomic surveillance more than four years into the pandemic.

The variant was first identified from a sample collected November 22, 2024, in South Africa [1]. It then appeared in Mozambique on March 17, 2025, the Netherlands on April 12, Germany on April 29, and gradually accumulated detections through the summer and fall of 2025 [1]. The median time between specimen collection and sequence reporting averaged 18 days globally, with a range from 3 to 123 days [1].

The CDC used a multimodal surveillance approach to track BA.3.2: the Traveler-Based Genomic Surveillance program (testing nasal swabs and airplane wastewater from international travelers), the National Wastewater Surveillance System (monitoring approximately 1,300 U.S. sites), the WastewaterSCAN partnership (150 sites), and digital surveillance of GISAID and GenBank sequence repositories [1].

Wastewater detection preceded clinical specimen identification by weeks in most states [1], reinforcing its value as an early warning system. But the fact that a variant could circulate undetected for roughly a year before attracting scientific attention underscores the limits of current surveillance — particularly in regions with less sequencing capacity.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Is the Coverage Proportionate?

Every COVID variant since Delta has followed a media cycle: detection, alarm, uncertainty, and then outcomes less severe than initial fears suggested. Cicada is arriving in that same pattern.

The variant accounts for a small fraction of U.S. cases. It has not been linked to increased severity. The WHO has assessed it as low additional risk [3]. Standard COVID tests remain effective at detecting it [3][7]. Antivirals still work [9][10].

Against that, 75 spike mutations represent genuine immunological novelty. Lab data showing reduced antibody neutralization is not nothing — it means more vaccinated and previously infected people may experience breakthrough infections, even if most remain protected from severe outcomes. The European data showing 30% prevalence demonstrates that Cicada can establish itself in highly vaccinated populations [1][3].

Jetelina, the epidemiologist behind "Your Local Epidemiologist," estimated that "a spring/summer wave is likely but neither negligible nor catastrophic" and argued that pandemic risk has actually decreased due to widespread population immunity from both infections and vaccination [4].

The proportionality question cuts both ways. Insufficient coverage of a variant that later surges would represent a failure to inform the public. But amplifying a low-prevalence variant with uncertain clinical significance — especially when hospitalizations are declining — risks reinforcing the pattern where each new variant name becomes a synonym for crisis regardless of the underlying data.

A reasonable threshold for escalated concern would be: evidence of increased severity in clinical data (not just lab assays), sustained growth displacing other variants, or rising hospitalization rates in regions with high Cicada prevalence. None of those thresholds have been met as of early April 2026.

What Happens If Cicada Drives a Wave?

If BA.3.2 does achieve dominance and trigger a significant wave, the downstream effects would follow familiar patterns: increased healthcare system strain, workforce absenteeism, and a potential uptick in long COVID incidence.

The 2024–2025 season's estimated 390,000–550,000 hospitalizations occurred without overwhelming hospital capacity in most regions [2], suggesting that a Cicada wave of similar or lesser magnitude would be manageable. The more concerning scenario is if immune evasion leads to a wave that is broader — affecting more people — even if individual cases are not more severe.

Policy levers remain limited. Masking guidance can be issued but is largely voluntary. Gathering limits and business closures lack political support and, in many jurisdictions, legal authority. The most viable interventions are targeted vaccination campaigns — particularly for high-risk groups — and ensuring antiviral supply chains can meet demand.

The federal government's pandemic infrastructure has contracted since 2023. Whether the remaining public health apparatus can mount an effective targeted response if Cicada surges will test systems that have been operating in a lower gear for more than two years.

The Bottom Line

BA.3.2 is real, genetically distinct, and spreading. Its 70–75 spike mutations make it the most divergent variant since the original Omicron emergence in late 2021. Lab data confirms reduced vaccine neutralization. It has established footholds in Europe and is growing in the United States.

But "genetically distinct" does not automatically mean "clinically dangerous." No data from any country where Cicada has reached significant prevalence shows an increase in hospitalizations or deaths. Antivirals work. Vaccines, while less effective at preventing infection, are expected to retain protection against severe disease. The variant's reduced ACE2 binding efficiency may be self-limiting.

The appropriate response — for public health officials, clinicians, and individuals — is continued surveillance, targeted vaccination of high-risk populations, and a calibrated assessment of risk based on clinical outcomes rather than mutation counts alone. Cicada warrants attention. Whether it warrants alarm remains an open question that only more data can answer.